The investigators performed single-cell RNA sequencing of peripheral blood mononuclear cells and computed pathway, cytokine response and transcription factor activity scores across cell populations. The study team observed that methamphetamine use pushed HIV-associated signatures in opposite directions across distinct lineages. In monocytes, methamphetamine was associated with shifts in interferon-related programs, antigen-presentation pathways and JAK–STAT signaling relative to PWH who did not use stimulants. In CD8+ T cells, the data indicated altered activity of IFN-γ, IL-2 and MYC programs in Meth+HIV participants. These findings suggest that methamphetamine modifies innate and adaptive arms differently, acting to reverse—or at least redirect—some HIV-associated immune alterations in a lineage-specific manner.
While several HIV-associated signatures were reversed in monocytes and CD8+ T cells, the cohort showed persistence of other dysregulated programs. The authors reported that proliferative signatures and TNF signaling linked to HIV remained active in CD4+ T cells and γδ T cells from Meth+HIV participants. That pattern implies selective resilience of particular inflammatory and proliferative pathways despite stimulant-associated modulation elsewhere in the immune compartment. The source did not report mechanistic dosing or temporal dynamics that would clarify whether these persistent programs reflect irreversible changes or a transient response to recent methamphetamine exposure.
Subpopulation analysis revealed lineage-specific nuance: central memory CD8+ T cells from PWH who use methamphetamine exhibited reduced type 1 effector program signatures. The study team observed this diminution of type 1 effector activity alongside the broader CD8+ T cell program shifts described above. Reduced effector programming in central memory CD8+ cells could have implications for antiviral control and tissue surveillance, though the source did not provide longitudinal clinical outcome data to connect these cellular signatures with functional immune failure or clinical endpoints.
The investigators extended their analysis to plasma using targeted proteomics in a larger participant set; the plasma cohort additionally included PWH who use cocaine as a stimulant comparator. Data indicated an HIV-associated cytotoxic lymphocyte activation signature—marked by elevations in KLRK1, IFN-γ, TNF, granzyme B and CXCL9. Methamphetamine use further amplified that cytotoxic activation signature. Plasma levels of IL-6, CXCL13 and neurofilament heavy chain were also higher in Meth+HIV participants compared with PWH without stimulant exposure, according to the authors. The study text did not supply absolute concentrations, p-values, or detailed comparator statistics within the summary material provided.
Network analysis of plasma proteins identified IFN-γ as the most connected protein in the interaction network assembled by the authors. IFN-γ sat at the interface between a cytotoxic module and a lymphoid chemokine module, suggesting it may coordinate cross-talk between cytotoxic effector activity and lymphoid-directed chemotaxis. Based on these observed relationships, the investigators nominated IFN-γ signaling—operating through monocyte antigen presentation and CD8+ T cell effector programs—together with TNF, IL-6 and CXCL13, as candidate mediators of neuroimmune dysfunction in PWH who use methamphetamine.
The investigation was cross-sectional and observational in design, combining single-cell transcriptomics on PBMCs with targeted plasma proteomics across defined participant groups: controls without HIV, PWH without methamphetamine use, PWH who use methamphetamine, and (for plasma only) PWH who use cocaine. The source reported that institutional review board approval was obtained and that participants gave written informed consent. The authors declared no competing interests and stated that data from the study are available upon reasonable request. The medRxiv posting date for the preprint is November 20, 2026.
Limitations and open questions documented in the source: the report did not include longitudinal follow-up to assess whether the observed immune signatures predict clinical or neurocognitive outcomes over time; specific sample sizes, statistical measures and effect sizes were not reported in the abstracted text provided; and experimental dosing, timing of stimulant exposure relative to sampling, and mechanistic causality were not described in the material summarized here. These gaps define immediate next steps for confirmatory work and clinical correlation.